Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4261 to 4275 of 8931 results

  1. Joint distraction for ankle osteoarthritis (HTG393)

    Evidence-based recommendations on joint distraction for ankle osteoarthritis in adults. This involves fixing a metal frame around the ankle and pulling the joint slightly apart using the frame to allow cartilage regrowth.

  2. Insertion of a subretinal prosthesis system for retinitis pigmentosa (HTG392)

    Evidence-based recommendations on insertion of a subretinal prosthesis system for retinitis pigmentosa. This involves performing a vitrectomy and implanting a microchip underneath the macula using a transscleral, then subretinal approach.

  3. Implanting a baroreceptor stimulation device for resistant hypertension (HTG387)

    Evidence-based recommendations on implanting a baroreceptor stimulation device for resistant hypertension. This involves using electrical impulses from the device that stimulate baroreceptors to help the body lower blood pressure.

  4. Single‑incision laparoscopic cholecystectomy (HTG361)

    Evidence-based recommendations on single incision laparoscopic cholecystectomy. This involves removing the gallbladder through a small cut, most often below the bellly button.

  5. Minimally invasive video‑assisted parathyroidectomy (HTG350)

    Evidence-based recommendations on minimally invasive video-assisted parathyroidectomy. This involves inserting surgical instruments through a small cut (keyhole surgery) to find and remove any abnormal glands.

  6. Endoscopic radiofrequency ablation for Barrett's oesophagus with low‑grade dysplasia or no dysplasia (HTG345)

    Evidence-based recommendations on endoscopic radiofrequency ablation for Barrett’s oesophagus with low-grade dysplasia or no dysplasia. This involves using radiofrequency (heat) energy to destroy the abnormal cells and promote the growth of healthy normal cells.

  7. Photochemical corneal collagen cross‑linkage using riboflavin and ultraviolet A for keratoconus and keratectasia (HTG319)

    Evidence-based recommendations on photochemical corneal cross linkage using riboflavin and ultraviolet A for keratoconus. This involves using special eye drops and exposing the eye ultraviolet light, with the aim to strengthen the cornea.

  8. Selective internal radiation therapy for primary hepatocellular carcinoma (HTG314)

    Evidence-based recommendations on selective internal radiation therapy (SIRT) for primary hepatocellular carcinoma. This involves infusion of microspheres loaded with yttrium-90, which aims to deliver radiation directly into the tumour, minimising the risk of radiation damage to healthy surrounding tissues.

  9. The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury (HTG356)

    Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury.

  10. E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta (HTG326)

    Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta.

  11. Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (HTG401)

    Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.

  12. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)

    Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.

  13. A new model for evaluating and purchasing antimicrobials in the UK

    Overview of NICE and NHS England’s pioneering subscription-style purchasing model for antimicrobials: its pilot with ceftazidime-avibactam and cefiderocol in 2022, expansion in 2024, supporting health technology assessments, downloadable guidance and procurement tools.

  14. Hypertension: ECG for target organ damage (IND123)

    This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 1 April to 31 March who have a record of a 12-lead ECG performed in the 3 months before or after the date of entry to the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM77

  15. Woundchek Protease Status for assessing elevated protease status in chronic wounds (MIB83)

    NICE has developed a medtech innovation briefing (MIB) on the Woundchek Protease Status for assessing elevated protease status in chronic wounds .